|Study Description:||The goal of this clinical research study is to learn if adding pegylated |
interferon-alfa 2a (Pegasys) to the TKI that you are already receiving can help
to control CML. The safety of this treatment combination will also be studied.
Pegasys is a form of the drug interferon. It is designed to help the body’s
immune system to fight infections. It may also affect the body’s response to
A TKI (imatinib mesylate, nilotinib, or dasatinib) is designed to bind to and
shut off a protein in tumor cells called Bcr-Abl. Shutting Bcr-Abl off may
prevent CML cells from growing, and may cause them to die.
You are already receiving a TKI. This consent form will describe the
administration of Pegasys, any tests and procedures that need to be performed
while you are receiving Pegasys, and any risks/benefits there may be from